Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Low‐molecular‐weight heparin showed no clear difference in major bleeding ( compared with no prophylaxis (moderate certainty).
Low‐molecular‐weight heparin showed no clear difference in minor bleeding ( compared with no prophylaxis (moderate certainty).
Lower blood pressure targets showed no clear difference in total mortality compared with standard blood pressure targets (moderate certainty).
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in total cardiovascular events compared with standard blood pressure targets (low certainty).
Lower blood pressure targets showed no clear difference in cardiovascular mortality compared with standard blood pressure targets (moderate certainty).
It is very uncertain whether lower blood pressure targets changes participant withdrawals due to adverse effects compared with standard blood pressure targets (very low certainty).
The review found no eligible studies for this question.
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
Low molecular weight heparin showed no clear difference in recurrent VTE compared with unfractionated heparin (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).